SHAREHOLDER ALERT: Weiss Law Investigates IVERIC bio, Inc.

NEW YORK, May 1, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of IVERIC bio, Inc. ("IVERIC" or the "Company") (NASDAQ: ISEE), in connection with its proposed acquisition by Astellas Pharma Inc.  Under the merger agreement, the Company's shareholders will receive $40.00 in cash for each share of IVERIC owned.  The transaction is valued at approximately $5.9 billion.